GMO regulations a ‘significant burden’ on gene therapy clinical trials – OutSourcing-Pharma.com
OutSourcing-Pharma.com |
GMO regulations a 'significant burden' on gene therapy clinical trials
OutSourcing-Pharma.com The Alliance for Regenerative Medicine (ARM) and other industry groups are urging regulators to consider gene therapy requirements in upcoming reforms, because some advanced therapy medicinal products (ATMPs), such as gene therapies, contain … |
